Compass Therapeutics (NASDAQ:CMPX) Stock Gets Price Target Cut from Wedbush

Posted by Brenda Bartman on Nov 13th, 2026

Compass Therapeutics (NASDAQ:CMPX – Free Report) had its target price lowered by Wedbush from $1.00 to $0.90 in a research note released on Tuesday morning,Benzinga reports. The brokerage currently has a neutral rating on the stock.

Several other analysts also recently issued reports on the company. Piper Sandler boosted their price target on Compass Therapeutics from $4.00 to $6.00 and gave the company an “overweight” rating in a research note on Friday, August 7th. Citizens Jmp lowered their price objective on Compass Therapeutics to $4.00 and set a “market outperform” rating on the stock in a research report on Wednesday, September 23rd. Citigroup reissued a “market outperform” rating on shares of Compass Therapeutics in a report on Wednesday, September 23rd. Guggenheim reduced their target price on shares of Compass Therapeutics to $4.00 and set a “buy” rating for the company in a research report on Wednesday, September 23rd. Finally, Lifesci Capital cut shares of Compass Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, September 22nd. One research analyst has rated the stock with a Strong Buy rating, twelve have assigned a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $9.99.

Check Out Our Latest Research Report on Compass Therapeutics

Compass Therapeutics Stock Down 1.2%

Shares of NASDAQ:CMPX opened at $0.82 on Tuesday. Compass Therapeutics has a 12-month low of $0.67 and a 12-month high of $6.88. The stock has a market cap of $147.67 million, a PE ratio of -1.74 and a beta of 1.06. The business has a 50 day moving average of $1.17 and a 200-day moving average of $3.00.

Compass Therapeutics (NASDAQ:CMPX – Get Free Report) last posted its earnings results on Monday, November 9th. The company reported ($0.15) EPS for the quarter, missing the consensus estimate of ($0.13) by ($0.02). Equities research analysts expect that Compass Therapeutics will post -0.52 earnings per share for the current year.

Institutional Trading of Compass Therapeutics

Several large investors have recently modified their holdings of the stock. BlackRock Inc. bought a new position in shares of Compass Therapeutics in the second quarter worth $24,707,000. Palo Alto Investors LP acquired a new stake in Compass Therapeutics during the second quarter worth about $12,771,670. Fisher Asset Management LLC grew its stake in Compass Therapeutics by 39.8% during the third quarter. Fisher Asset Management LLC now owns 1,945,821 shares of the company’s stock worth $2,024,000 after buying an additional 553,931 shares in the last quarter. Squarepoint Ops LLC grew its stake in Compass Therapeutics by 1,906.9% during the second quarter. Squarepoint Ops LLC now owns 1,007,507 shares of the company’s stock worth $2,206,000 after buying an additional 957,305 shares in the last quarter. Finally, Seven Fleet Capital Management LP increased its holdings in Compass Therapeutics by 65.4% in the 1st quarter. Seven Fleet Capital Management LP now owns 940,538 shares of the company’s stock valued at $4,975,000 after buying an additional 371,791 shares during the period. 68.43% of the stock is owned by institutional investors and hedge funds.

Compass Therapeutics Company Profile

(Get Free Report)

Compass Therapeutics is a clinical-stage biotechnology company focused on developing antibody-based medicines for cancer. The company’s research centers on immuno-oncology and other approaches intended to target biological pathways involved in tumor growth and the body’s immune response. One of its investigational programs is CTX-009, a bispecific antibody designed to target DLL4 and VEGF-A, proteins associated with tumor blood-vessel development. Compass is also advancing other antibody programs for potential use against solid tumors.